American Association for the Study of Liver Diseases. New MASLD nomenclature. 2024. https://www.aasld.org/new-masld-nomenclature. Accessed 4 Apr 2024.

Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–86.

Article  PubMed  Google Scholar 

Harrison SA, Gawrieh S, Roberts K, et al. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol. 2021;75(2):284–91.

Article  PubMed  Google Scholar 

Sangro P, de la Torre AM, Sangro B, D’Avola D. Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment. J Physiol Biochem. 2023;79(4):869–79.

Article  PubMed  PubMed Central  Google Scholar 

Dufour JF. A pivotal year for NAFLD and NASH therapeutics. Nat Rev Endocrinol. 2024;20(2):75–6.

Article  PubMed  Google Scholar 

Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497–509.

Article  PubMed  Google Scholar 

Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–835.

Article  PubMed  Google Scholar 

Cusi K. Selective agonists of thyroid hormone receptor beta for the treatment of NASH. N Engl J Med. 2024;390(6):559–61.

Article  PubMed  Google Scholar 

Madrigal Pharmaceuticals Inc. Madrigal Pharmaceuticals announces FDA approval of Rezdiffra™ (resmetirom) for the treatment of patients with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis [media release]. 14 Mar 2024. https://www.madrigalpharma.com/.

Madrigal Pharmaceuticals Inc. Resmetirom: US prescribing information. 2024. https://www.rezdiffra.com/. Accessed 18 Mar 2024.

US Food & Drug Administration. FDA approves first treatment for patients with liver scarring due to fatty liver disease [media release]. 14 Mar 2024. https://www.fda.gov/.

Madrigal Pharmaceuticals Inc. Madrigal Pharmaceuticals announces EMA validation of its marketing authorization application for resmetirom for the treatment of NASH/MASH with liver fibrosis [media release]. 5 Mar 2024. https://www.madrigalpharma.com.

VIA Pharmaceuticals Inc. VIA Pharmaceuticals licenses drug candidates from Roche to expand cardiovascular pipeline to include metabolic disease [media release]. 23 Dec 2008. https://www.medindia.net/.

Madrigal Pharmaceuticals Inc. Form 10-K. 2024. https://ir.madrigalpharma.com/. Accessed 3 Apr 2024.

Kelly MJ, Pietranico-Cole S, Larigan JD, et al. Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a highly selective thyroid hormone receptor β agonist in clinical trials for the treatment of dyslipidemia. J Med Chem. 2014;57(10):3912–23.

Article  CAS  PubMed  Google Scholar 

Hönes GS, Sivakumar RG, Hoppe C, et al. Cell-specific transport and thyroid hormone receptor isoform selectivity account for hepatocyte-targeted thyromimetic action of MGL-3196. Int J Mol Sci. 2022;23:13714.

Article  PubMed  PubMed Central  Google Scholar 

Kannt A, Wohlfart P, Madsen AN, et al. Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis. Br J Pharmacol. 2021;178(12):2412–23.

Article  CAS  PubMed  Google Scholar 

Feigh M, Nohr-Meldgaard J, Pors S, Hansen HB. Preclinical efficacy and clinical translatability of resmetirom in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH [abstract no. WED-543 plus poster]. J Hepatol. 2023;78(Suppl 1):S800.

Article  Google Scholar 

Taub R, Chiang E, Chabot-Blanchet M, et al. Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist. Atherosclerosis. 2013;230(2):373–80.

Article  CAS  PubMed  Google Scholar 

Harrison SA, Taub R, Neff GW, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2023;29(11):2919–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hovingh GK, Klausen IC, Heggen E, et al. Resmetirom (MGL-3196) in patients with heterozygous familial hypercholesterolemia. J Am Coll Cardiol. 2022;79(12):1220–2.

Article  CAS  PubMed  Google Scholar 

Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394(10213):2012–24.

Article  CAS  PubMed  Google Scholar